Amfetamine modified release - Highland Therapeutics

Drug Profile

Amfetamine modified release - Highland Therapeutics

Alternative Names: D-amphetamine sulfate capsules; Dexamfetamine modified release - Highland Therapeutics; Dextroamphetamine sulfate modified release - Highland Therapeutics; HLD 900; HLD-100

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Highland Therapeutics
  • Developer Highland Therapeutics; Ironshore Pharmaceutical and Development
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder
  • Clinical Phase Unknown Bulimia nervosa

Most Recent Events

  • 12 Apr 2017 Ironshore Pharmaceuticals announces intention to submit NDA to the US FDA for Attention deficit hyperactivity disorder in 2018
  • 12 Apr 2017 Safety and efficacy data from a phase II trial in Attention deficit disorder released by Ironshore Pharmaceuticals
  • 12 Apr 2017 Ironshore Pharmaceuticals plans pivotal phase III trials for Attention deficit hyperactivity disorder in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top